Fanconi anaemia: From a monogenic disease to sporadic cancer

Clinical and Translational Oncology

Volumn 13, Issue 4, 2011, Pages 215-221

  Valeri, Antonio ^a   Martínez, Sandra ^a,b   Casado, José A ^a   Bueren, Juan A ^a  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^b PHARMAMAR S A   (Spain)

Author keywords

Acute myeloid leukemia; Chronic myeloid leukemia; Fanconi anaemia; PARP inhibitors; Sporadic cancer Cross linkers; Synthetic lethality

Indexed keywords

FANCONI ANEMIA PROTEIN; TRABECTEDIN;

CANCER GROWTH; CHRONIC MYELOID LEUKEMIA; DISEASE ASSOCIATION; DNA CROSS LINKING; DNA REPAIR; DRUG MECHANISM; FANCONI ANEMIA; GENETIC ASSOCIATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR PATHOLOGY; PROGNOSIS; REVIEW;

EID: 79960688447     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-011-0645-6     Document Type: Review

References (77)

1. Kutler DI, Singh B, Satagopan J et al (2003) A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 101:1249-1256 (Pubitemid 36182492)
2. Du W, Adam Z, Rani R et al (2008) Oxidative stress in Fanconi anemia hematopoiesis and disease progression. Antioxid Redox Signal 10:1909-1921
3. Vaz F, Hanenberg H, Schuster B et al (2010) Mutation of the RAD51C gene in a Fanconi anemialike disorder. Nat Genet 42:406-409
4. Kee Y, D'Andrea AD (2010) Expanded roles of the Fanconi anemia pathway in preserving genomic stability. Genes Dev 24:1680-1694
5. Meetei AR, de Winter JP, Medhurst AL et al (2003) A novel ubiquitin ligase is deficient in Fanconi anemia. Nat Genet 35:165-170 (Pubitemid 37187635)
6. Ali AM, Singh TR, Meetei AR (2009) FANCMFAAP24 and FANCJ: FA proteins that metabolize DNA. Mutat Res 668:20-26
7. Garcia-Higuera I, Taniguchi T, Ganesan S et al (2001) Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 7:249-262 (Pubitemid 32206493)
8. Smogorzewska A, Matsuoka S, Vinciguerra P et al (2007) Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell 129:289-301 (Pubitemid 46584733)
9. MacKay C, Declais AC, Lundin C et al (2010) Identification of KIAA1018/FAN1, a DNA repair nuclease recruited to DNA damage by monoubiquitinated FANCD2. Cell 142:65-76
10. Liu T, Ghosal G, Yuan J et al (2010) FAN1 acts with FANCI-FANCD2 to promote DNA interstrand cross-link repair. Science 329:693-696
11. Smogorzewska A, Desetty R, Saito TT et al (2010) A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease necessary for DNA interstrand crosslink repair. Mol Cell 39:36-47
12. Kratz K, Schopf B, Kaden S et al (2010) Deficiency of FANCD2-associated nuclease KIAA1018/FAN1 sensitizes cells to interstrand crosslinking agents. Cell 142:77-88
13. Knipscheer P, Raschle M, Smogorzewska A et al (2009) The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair. Science 326:1698-1701
14. Nijman SM, Huang TT, Dirac AM et al (2005) The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol Cell 17:331-339 (Pubitemid 40193305)
15. Rego MA, Kolling FWt, Howlett NG (2009) The Fanconi anemia protein interaction network: casting a wide net. Mutat Res 668:27-41
16. Andreassen PR, D'Andrea AD, Taniguchi T (2004) ATR couples FANCD2 monoubiquitination to the DNA-damage response. Genes Dev 18:1958-1963 (Pubitemid 39071576)
17. Pichierri P, Franchitto A, Rosselli F (2004) BLM and the FANC proteins collaborate in a common pathway in response to stalled replication forks. EMBO J 23:3154-3163 (Pubitemid 39093609)
18. New HV, Cale CM, Tischkowitz M et al (2005) Nijmegen breakage syndrome diagnosed as Fanconi anaemia. Pediatr Blood Cancer 44:494-499 (Pubitemid 40614498)
19. Garcia MJ, Benitez J (2008) The Fanconi anaemia/BRCA pathway and cancer susceptibility. Searching for new therapeutic targets. Clin Transl Oncol 10:78-84
20. Lyakhovich A, Surralles J (2006) Disruption of the Fanconi anemia/BRCA pathway in sporadic cancer. Cancer Lett 232:99-106 (Pubitemid 43053937)
21. Tischkowitz M, Ameziane N, Waisfisz Q et al (2003) Biallelic silencing of the Fanconi anaemia gene FANCF in acute myeloid leukaemia. Br J Haematol 123:469-471 (Pubitemid 37363488)
22. Taniguchi T, Tischkowitz M, Ameziane N et al (2003) Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 9:568-574 (Pubitemid 36597103)
23. Narayan G, Arias-Pulido H, Nandula SV et al (2004) Promoter hypermethylation of FANCF: disruption of Fanconi anemia-BRCA pathway in cervical cancer. Cancer Res 64:2994-2997 (Pubitemid 38581394)
24. Marsit CJ, Liu M, Nelson HH et al (2004) Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 23:1000-1004 (Pubitemid 38250946)
25. Dhillon VS, Shahid M, Husain SA (2004) CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin. Mol Cancer 3:33
26. Wei M, Xu J, Dignam J et al (2008) Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers. Breast Cancer Res Treat 111:113-120 (Pubitemid 352009235)
27. Neveling K, Kalb R, Florl AR et al (2007) Disruption of the FA/BRCA pathway in bladder cancer. Cytogenet Genome Res 118:166-176 (Pubitemid 350125253)
28. Teodoridis JM, Hall J, Marsh S et al (2005) CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 65:8961-8967 (Pubitemid 41377387)
29. Ameziane N, Chen F, Leemans CR et al (2009) No evidence for FANCF gene silencing in headand-neck squamous cell carcinomas. Cell Oncol 31:53-56
30. Meyer S, White DJ, Will AM et al (2006) No evidence of significant silencing of Fanconi genes FANCF and FANCB or Nijmegen breakage syndrome gene NBS1 by DNA hyper-methylation in sporadic childhood leukaemia. Br J Haematol 134:61-63 (Pubitemid 43830029)
31. Tischkowitz MD, Morgan NV, Grimwade D et al (2004) Deletion and reduced expression of the Fanconi anemia FANCA gene in sporadic acute myeloid leukemia. Leukemia 18:420-425 (Pubitemid 38425854)
32. Condie A, Powles RL, Hudson CD et al (2002) Analysis of the Fanconi anaemia complementation group A gene in acute myeloid leukaemia. Leuk Lymphoma 43:1849-1853 (Pubitemid 34874021)
33. Lensch MW, Tischkowitz M, Christianson TA et al (2003) Acquired FANCA dysfunction and cytogenetic instability in adult acute myelogenous leukemia. Blood 102:7-16 (Pubitemid 36759629)
34. van der Heijden MS, Yeo CJ, Hruban RH, Kern SE (2003) Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res 63:2585-2588 (Pubitemid 36605199)
35. Palagyi A, Neveling K, Plinninger U et al (2010) Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents. Mol Cancer 9:127
36. Foster KA, Harrington P, Kerr J et al (1996) Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer. Cancer Res 56:3622-3625 (Pubitemid 26271999)
37. Hilton JL, Geisler JP, Rathe JA et al (2002) Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 94:1396-1406 (Pubitemid 35154144)
38. Rio PG, Pernin D, Bay JO et al (1998) Loss of heterozygosity of BRCA1, BRCA2 and ATM genes in sporadic invasive ductal breast carcinoma. Int J Oncol 13:849-853 (Pubitemid 28435363)
39. Katsama A, Sourvinos G, Zachos G, Spandidos DA (2000) Allelic loss at the BRCA1, BRCA2 and TP53 loci in human sporadic breast carcinoma. Cancer Lett 150:165-170 (Pubitemid 30125850)
40. Janatova M, Zikan M, Dundr P et al (2005) Novel somatic mutations in the BRCA1 gene in sporadic breast tumors. Hum Mutat 25:319
41. Zhang J, Zhao D, Park HK et al (2010) FAVL elevation in human tumors disrupts Fanconi anemia pathway signaling and promotes genomic instability and tumor growth. J Clin Invest 120:1524-1534
42. Deutsch E, Jarrousse S, Buet D et al (2003) Downregulation of BRCA1 in BCR-ABL-expressing hematopoietic cells. Blood 101:4583-4588 (Pubitemid 36857831)
43. Wolanin K, Magalska A, Kusio-Kobialka M et al (2010) Expression of oncogenic kinase Bcr-Abl impairs mitotic checkpoint and promotes aberrant divisions and resistance to microtubule-targeting agents. Mol Cancer Ther 9:1328-1338
44. Valeri A, Alonso-Ferrero ME, Rio P et al (2010) Bcr/Abl interferes with the Fanconi anemia/BRCA pathway: implications in the chromosomal instability of chronic myeloid leukemia cells. PLoS One 5:e15525
45. Niedernhofer LJ, Lalai AS, Hoeijmakers JH (2005) Fanconi anemia (cross)linked to DNA repair. Cell 123:1191-1198 (Pubitemid 41821778)
46. Rothfuss A, Grompe M (2004) Repair kinetics of genomic interstrand DNA cross-links: evidence for DNA double-strand break-dependent activation of the Fanconi anemia/BRCA pathway. Mol Cell Biol 24:123-134 (Pubitemid 38010040)
47. Moldovan GL, D'Andrea AD (2009) How the Fanconi anemia pathway guards the genome. Annu Rev Genet 43:223-249
48. Helleday T, Petermann E, Lundin C et al (2008) DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 8:193-204 (Pubitemid 351301852)
49. Villarroel MC, Rajesh Kumar NV, Garrido-Laguna I et al (2011) Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther 10:3-8
50. Casado JA, Rio P, Marco E et al (2008) Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin. Mol Cancer Ther 7:1309-1318
51. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/ medicines/000773/human-med-001165.jsp&murl=menus/medicines/medicines. jsp&jsenabled=true
52. Marco E, Garcia-Nieto R, Mendieta J et al (2002) A 3.(ET743)-DNA complex that both resembles an RNA-DNA hybrid and mimicks zinc fingerinduced DNA structural distortions. J Med Chem 45:871-880 (Pubitemid 34173937)
53. Litman R, Gupta R, Brosh RM Jr, Cantor SB (2008) BRCA-FA pathway as a target for anti-tumor drugs. Anticancer Agents Med Chem 8:426-430 (Pubitemid 351761427)
54. Landais I, Hiddingh S, McCarroll M et al (2009) Monoketone analogs of curcumin, a new class of Fanconi anemia pathway inhibitors. Mol Cancer 8:133
55. Landais I, Sobeck A, Stone S et al (2009) A novel cell-free screen identifies a potent inhibitor of the Fanconi anemia pathway. Int J Cancer 124:783-792
56. Burkitt K, Ljungman M (2008) Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin. Mol Cancer 7:24
57. Gallmeier E, Hucl T, Brody JR et al (2007) Highthroughput screening identifies novel agents eliciting hypersensitivity in Fanconi pathway-deficient cancer cells. Cancer Res 67:2169-2177 (Pubitemid 46424236)
58. Kaelin WG Jr (2005) The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5:689-698 (Pubitemid 41486362)
59. Chen CC, Kennedy RD, Sidi S et al (2009) CHK1 inhibition as a strategy for targeting Fanconi anemia (FA) DNA repair pathway deficient tumors. Mol Cancer 8:24
60. Farmer H, McCabe N, Lord CJ et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-921 (Pubitemid 40559006)
61. Bryant HE, Schultz N, Thomas HD et al (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913-917 (Pubitemid 40559005)
62. McCabe N, Turner NC, Lord CJ et al (2006) Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 66:8109-8115 (Pubitemid 44299177)
63. http://www.cancer.gov/clinicaltrials/OSU-09100
64. Ceccaldi R, Briot D, Larghero J et al (2011) Spon taneous abrogation of the G2 DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients. J Clin Invest 121:184-194
65. Cucer N, Taheri S, Ok E, Ozkul Y (2008) Methylation status of CpG islands at sites -59 to +96 in exon 1 of the BRCA2 gene varies in mammary tissue among women with sporadic breast cancer. J Genet 87:155-158
66. Smith IM, Mithani SK, Mydlarz WK et al (2010) Inactivation of the tumor suppressor genes causing the hereditary syndromes predisposing to head and neck cancer via promoter hypermethylation in sporadic head and neck cancers. ORL J Otorhinolaryngol Relat Spec 72:44-50
67. Hess CJ, Ameziane N, Schuurhuis GJ et al (2008) Hypermethylation of the FANCC and FANCL promoter regions in sporadic acute leukaemia. Cell Oncol 30:299-306 (Pubitemid 352032906)
68. Olopade OI, Wei M (2003) FANCF methylation contributes to chemoselectivity in ovarian cancer. Cancer Cell 3:417-420 (Pubitemid 38340287)
69. Koul S, McKiernan JM, Narayan G et al (2004) Role of promoter hypermethylation in cisplatin treatment response of male germ cell tumors. Mol Cancer 3:16
70. Lim SL, Smith P, Syed N et al (2008) Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer. Br J Cancer 98:1452-1456 (Pubitemid 351543586)
71. Wang Z, Li M, Lu S et al (2006) Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway. Cancer Biol Ther 5:256-260
72. Potapova A, Hoffman AM, Godwin AK et al (2008) Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer. Cancer Res 68:998-1002 (Pubitemid 351272217)
73. Weber BH, Brohm M, Stec I et al (1996) A somatic truncating mutation in BRCA2 in a sporadic breast tumor. Am J Hum Genet 59:962-964 (Pubitemid 26328096)
74. Kwiatkowska E, Teresiak M, Breborowicz D, Mackiewicz A (2002) Somatic mutations in the BRCA2 gene and high frequency of allelic loss of BRCA2 in sporadic male breast cancer. Int J Cancer 98:943-945 (Pubitemid 34286695)
75. Sparano A, Quesnelle KM, Kumar MS et al (2006) Genome-wide profiling of oral squamous cell carcinoma by array-based comparative genomic hybridization. Laryngoscope 116:735-741 (Pubitemid 44318029)
76. Zikan M, Janatova M, Pavlista D, Pohlreich P (2007) High frequency of BRCA1/2 and p53 somatic inactivation in sporadic ovarian cancer. J Genet 86:169-171 (Pubitemid 350005742)
77. Taniguchi T, D'Andrea AD (2006) Molecular pathogenesis of Fanconi anemia: recent progress. Blood 107:4223-4233 (Pubitemid 43801344)